Matthew Weston

Stock Analyst at UBS

(1.98)

# 2,878

Out of 4,754 analysts

3

Total ratings

100%

Success rate

1.33%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General

Stocks Rated by Matthew Weston

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NVS Novartis AG	Downgrades: Neutral	n/a	$110.62	-	1	Feb 13, 2025
	AZN AstraZeneca	Upgrades: Buy	n/a	$76.10	-	2	Feb 13, 2025

Novartis AG

Feb 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $110.62

Upside: -

AstraZeneca

Feb 13, 2025

Upgrades: Buy

Price Target: n/a

Current: $76.10

Upside: -